NEW YORK (GenomeWeb) – Cantor Fitzgerald on Tuesday initiated coverage of urine-based liquid biopsy firm Trovagene with a Buy rating and a $10 target price on the firm's stock. 

Analyst Bryan Brokmeier said in a research report that the company's differentiated approach to cancer detection and monitoring positions it to be "a leading player in the cancer diagnostics market." 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.